Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27589134 | 1.00 | USP5 (1.00) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL11985527 | 0.88 | USP5 (0.78) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL6098718 | 0.87 | TSHR (1.00) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL38661206 | 0.84 | USP5 (0.71) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL2614340 | 0.82 | USP5 (0.69) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL31303320 | 0.82 | USP5 (0.69) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL21459432 | 0.82 | USP5 (0.69) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL21459433 | 0.82 | USP5 (0.69) | USP5TSHRKMT2AGAAHTT | |
| SCHEMBL80194 | 0.81 | USP5 (0.68) | USP5TSHRKMT2AMAPTLMNA | |
| SCHEMBL311956 | 0.81 | USP5 (0.68) | USP5TSHRKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2308845-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308844-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308846-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101348455-A | Aspartic acid specificity cysteine proteinase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-01-21 | — | — | CN | disclosed |
| CN-100415718-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| CN-1420872-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | USP5 403/4885TSHR 4750/4885KMT2A 3925/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | USP5 403/4885TSHR 4750/4885KMT2A 3925/4885 |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | USP5 403/4885TSHR 4750/4885KMT2A 3925/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | USP5 359/4885TSHR 4820/4885KMT2A 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.